TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21159430

Group type: EXPERIMENTAL
Intervention: Anodal transcutaneous spinal cord direct current stimulation (tsDCS) at 2mA for 15 minutes
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Active tsDCS
Number of subjects: 11
Study: 19590458

Group type: EXPERIMENTAL
Intervention: CEE/MPA (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Red clover (120 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Black cohosh (128 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 17919253

Group type: EXPERIMENTAL
Intervention: AdheSE
Number of subjects: 50

Group type: COMPARATOR
Intervention: Excite
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both adhesive systems
Number of subjects: 50
Study: 15497663

Group type: COMPARATOR
Intervention: Azithromycin 500 mg tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Azithromycin 200 mg/5 mL suspension
Number of subjects: 24

Group type: COMPARATOR
Intervention: Azithromycin (both formulations)
Number of subjects: 24
Study: 11547053

Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ureteroscopy
Number of subjects: 64
Study: 9331518

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg once daily for 10 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg once daily for 10 days + Selegiline 10 mg once daily for 4 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg once daily for 4 days after citalopram washout
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7932291

Group type: EXPERIMENTAL
Intervention: 3-day time-management training program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (did not attend training)
Number of subjects: 56
Study: 2831262

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS) 1% solution, 0.13 ml nasal spray, administered at least twice daily
Number of subjects: 36
Study: 31689138

Group type: EXPERIMENTAL
Intervention: New class I Medical Device (MD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sunscreen alone (SPF 100+)
Number of subjects: 90
Study: 31768718

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention for encopresis (MIE); Treatment for constipation, 10-day behavioral intervention utilizing suppositories
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 20
Study: 27003676

Group type: EXPERIMENTAL
Intervention: Reread‐Adapt and Answer‐Comprehend (RAAC) + Goal Setting intervention
Number of subjects: 5
Study: 26833928

Group type: EXPERIMENTAL
Intervention: Learn to forgive group programme
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison group (90-minute video on forgiveness)
Number of subjects: 36
Study: 26311155

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 69
Study: 24034150

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard staging algorithm
Number of subjects: 223
Study: 21950699

Group type: EXPERIMENTAL
Intervention: Blue light-filtering IOL (acrysof IQ (SN60WF) [Alcon])
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clear IOL (Tecnis (Z9003) [AMO])
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both IOL groups
Number of subjects: 50
Study: 19006027

Group type: EXPERIMENTAL
Intervention: PTRA + ILBT
Number of subjects: 71

Group type: COMPARATOR
Intervention: PTRA
Number of subjects: 71
Study: 17032439

Group type: EXPERIMENTAL
Intervention: Long-menu questions (LMQs)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Open-ended questions (OEQs)
Number of subjects: 146
Study: 12848218

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10371003

Group type: COMPARATOR
Intervention: Interocclusal appliance therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Therapeutic jaw exercises
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Follow-up questionnaire (1-4 years after treatment)
Number of subjects: 26
Study: 8592096

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of epinephrine at 12.5, 25, and 50 ng/(kg x min) for 1 hour each
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 21
Study: 10149510

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass circuits
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonheparin-coated cardiopulmonary bypass circuits
Number of subjects: 14
Study: 6362341

Group type: EXPERIMENTAL
Intervention: 50-150 mg Slow Apresoline once daily
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Acetylator phenotyping
Number of subjects: 118
Study: 31610435

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neutral placebo training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CBM training combined with oxytocin
Number of subjects: 100
Study: 28371567

Group type: EXPERIMENTAL
Intervention: Insulin peglispro
Number of subjects: 388

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 388
Study: 26831302

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg for 7 days, 1.2 mg for 7 days, and 1.8 mg for 3 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 21
Study: 25110991

Group type: EXPERIMENTAL
Intervention: HCGM application for smartphones
Number of subjects: 63

Group type: COMPARATOR
Intervention: Paging only
Number of subjects: 63
Study: 22799482

Group type: EXPERIMENTAL
Intervention: 3-year after-school physical activity program (80 minutes of moderate-to-vigorous PA each school day)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 574
Study: 20738780

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg intravenous infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Somatostatin (250 mg/h after an initial bolus of 250 mg)
Number of subjects: 20
Study: 18439694

Group type: EXPERIMENTAL
Intervention: 24 Gy in 12 fractions (ARM A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 Gy in five fractions (ARM B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both arms (ARM A and ARM B)
Number of subjects: 60
Study: 15808246

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sub-Tenon's capsule injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Number of subjects: 61
Study: 14623837

Group type: EXPERIMENTAL
Intervention: Blood cultures (BCs) performed
Number of subjects: 289
Study: 10979930

Group type: EXPERIMENTAL
Intervention: DTP/Hib and 7VPnC (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTP and 7VPnC/Hib (group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTP/Hib (group 1)
Number of subjects: 0
Study: 8741722

Group type: EXPERIMENTAL
Intervention: Complaints Management Training (CMT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Anxiety Management Training (AMT)
Number of subjects: 19
Study: 1313068

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.6 mg/kg intravenously as a loading dose followed by 0.2 mg/kg every 6 h for 5 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 65
Study: 3874573

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31226457

Group type: EXPERIMENTAL
Intervention: Presence of Modic changes (MCs) at baseline and 1-year follow-up after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with MCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with and without MCs reporting neck pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with and without MCs reporting disabling arm pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of MCs
Number of subjects: 0
Study: 29976234

Group type: EXPERIMENTAL
Intervention: Sanitation only arm
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Combined WSH arm
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Combined WSH and Nutrition arm
Number of subjects: 4169
Study: 27916752

Group type: EXPERIMENTAL
Intervention: Novel therapy (including molecular target drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study: 25428346

Group type: EXPERIMENTAL
Intervention: Website B (interactive website with prescribed breakfast cereals)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Website A (standard advice on weight loss)
Number of subjects: 180
Study: 23510752

Group type: EXPERIMENTAL
Intervention: Intervention group (INT)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 502
Study: 20506953

Group type: EXPERIMENTAL
Intervention: Posterior dynamic transpedicular stabilization
Number of subjects: 46

Group type: COMPARATOR
Intervention: Posterior rigid transpedicular stabilization with fusion
Number of subjects: 46
Study: 18155988

Group type: EXPERIMENTAL
Intervention: Higher-energy-density entrée (2.0 kcal/g)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lower-energy-density entrée (30% lower in energy density)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lower-energy-density entrée
Number of subjects: 77
Study: 16437365

Group type: EXPERIMENTAL
Intervention: Single-canal jejunum interposition (group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: P pouch with Roux-en-Y esophagojejunostomy (group B)
Number of subjects: 31
Study: 12927342

Group type: EXPERIMENTAL
Intervention: Dynamic visual noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial tapping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual interference with real objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial tapping with same material
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corsi test
Number of subjects: 0
Study: 10787768

Group type: EXPERIMENTAL
Intervention: Information packet
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Action plan packet
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Both packets
Number of subjects: 536

Group type: COMPARATOR
Intervention: Neither packet
Number of subjects: 536
Study: 8843498

Group type: EXPERIMENTAL
Intervention: Insulin pump treatment
Number of subjects: 358

Group type: COMPARATOR
Intervention: Injection therapy
Number of subjects: 358
Study: 1364273

Group type: EXPERIMENTAL
Intervention: Oxatomide (Tinset) tablets
Number of subjects: 57
Study: 31462937

Group type: EXPERIMENTAL
Intervention: Intervention aimed at increasing physical activity
Number of subjects: 0
Study: 29770502

Group type: EXPERIMENTAL
Intervention: Father advocate intervention
Number of subjects: 66
Study: 27075863

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg and 80 mg
Number of subjects: 212
Study: 25312202

Group type: EXPERIMENTAL
Intervention: Reappraisal during the menstrual phase
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reappraisal during the mid‐late luteal phase
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Emotion regulation across menstrual phases
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neuroticism impact on emotion regulation
Number of subjects: 36
Study: 22460469

Group type: EXPERIMENTAL
Intervention: Energy restriction (500 kcal) and resistance training (RT) 3 days/week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Minimal care
Number of subjects: 27
Study: 19676097

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 246
Study: 17914201

Group type: EXPERIMENTAL
Intervention: Topical 2% cyclosporine drops
Number of subjects: 30
Study: 18607380

Group type: EXPERIMENTAL
Intervention: parent‐centered nutrition lifestyle program
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: child‐centered physical activity skill development program
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: both the programs
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study: 15384858

Group type: EXPERIMENTAL
Intervention: Urokinase therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ventriculostomy alone (Control)
Number of subjects: 27
Study: 11320545

Group type: EXPERIMENTAL
Intervention: TPS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SCC
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TPS and SCC
Number of subjects: 84
Study: 9291051

Group type: EXPERIMENTAL
Intervention: Duplex sonography with intravenous ultrasound contrast agent (Levovist)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Duplex sonography
Number of subjects: 113

Group type: COMPARATOR
Intervention: Contrast-enhanced CT scanning
Number of subjects: 113
Study: 8203337

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 36
Study: 3555588

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (C50)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg (HCTZ 25)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg and Hydrochlorothiazide 25 mg (C50/HCTZ 25)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 31634877

Group type: EXPERIMENTAL
Intervention: Medication Therapy Management program (MTM)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 392
Study: 30477922

Group type: EXPERIMENTAL
Intervention: Neutral zone (NZ) dentures
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 52
Study: 28988514

Group type: EXPERIMENTAL
Intervention: Acoustic reafference training with increased tempo (fast group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acoustic reafference training with decreased tempo (slow group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no manipulation of tempo
Number of subjects: 0
Study: 25799402

Group type: COMPARATOR
Intervention: Placebo without exercise
Number of subjects: 409

Group type: COMPARATOR
Intervention: Vitamin D (800 IU/d) without exercise
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo and exercise
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/d) and exercise
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 409
Study: 24332569

Group type: EXPERIMENTAL
Intervention: Benson's relaxation technique
Number of subjects: 86
Study: 23159254

Group type: EXPERIMENTAL
Intervention: Pictorial warning labels
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Pictorial warning labels with graphic imagery
Number of subjects: 981

Group type: COMPARATOR
Intervention: Text-only labels
Number of subjects: 981
Study: 19019476

Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg twice-daily
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Exenatide with MET or MET and SU
Number of subjects: 466
Study: 17955656

Group type: EXPERIMENTAL
Intervention: Lianbai liquid (prevention group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group I (advice only)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Lianbai liquid (treatment group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group II (norfloxacin)
Number of subjects: 126
Study: 15763649

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) comprising vincristine, etoposide, carboplatin, and cyclophosphamide followed by craniospinal RT 35 Gy/21 fractions with a posterior fossa boost 20 Gy/12 fractions.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) followed by craniospinal RT with a metastatic boost.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) prior to RT.
Number of subjects: 68
Study: 12197849

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (81 mg daily for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 7 days)
Number of subjects: 24
Study: 9860148

Group type: EXPERIMENTAL
Intervention: M1 (generic mefloquine tablet)
Number of subjects: 18

Group type: COMPARATOR
Intervention: M2 (reference mefloquine tablet)
Number of subjects: 18
Study: 7611126

Group type: EXPERIMENTAL
Intervention: encainide‐flecainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: moricizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 2564948

Group type: COMPARATOR
Intervention: Nasal challenge with Trichophyton tonsurans extract (double-blind, placebo-controlled)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bronchial provocation with Trichophyton tonsurans extract
Number of subjects: 12
Study: 1263629

Group type: EXPERIMENTAL
Intervention: Nurse practitioner with more frequent and longer patient visits, ordered more medications, less physician consultation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse practitioner who was more dependent on physicians for validation of her actions.
Number of subjects: 0
Study: 30641815

Group type: EXPERIMENTAL
Intervention: Full ozone therapy plus standard regular diabetic foot ulcer treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine diabetic foot care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Full ozone therapy
Number of subjects: 200
Study: 29044006

Group type: EXPERIMENTAL
Intervention: Cryotherapy combined with interferon
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 100
Study: 25536540

Group type: EXPERIMENTAL
Intervention: Fundamental Integrative Training (FIT) group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FIT group
Number of subjects: 41
Study: 24422341

Group type: EXPERIMENTAL
Intervention: Bhastrika pranayama (bellows breathing)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Breath awareness
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control session (non-yoga)
Number of subjects: 70
Study: 21291323

Group type: EXPERIMENTAL
Intervention: 2.0 million international units of IL-2 subcutaneously daily during the final 2 weeks of treatment interruption and the first week of treatment reinitiation (Arm A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 4.5 million international units of IL-2 subcutaneously twice a day during the first 5 days of treatment reinitiation (Arm B)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 21
Study: 19374158

Group type: EXPERIMENTAL
Intervention: salbutamol and budesonide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: salbutamol, budesonide and montelukast
Number of subjects: 50

Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 50
Study: 17268388

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BT-A) injections (3 successive doses to the calf muscle bilaterally at intervals of 3 to 4 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 60
Study: 15106100

Group type: EXPERIMENTAL
Intervention: Vaccination at 15 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccination at 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccination at 9 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccination at 9 months (children of mothers born in or before 1963)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccination at 9 months, 12 months, and 15 months
Number of subjects: 0
Study: 11168742

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride mouthrinse (ASF)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Alcohol-free chlorhexidine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.15% triclosan solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.02% triclosan solution
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 19
Study: 9597565

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7890436

Group type: EXPERIMENTAL
Intervention: Cellulose triacetate (CTA) membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuprophan (C) membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 3371085

Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg) plus Amiloride (5 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg) plus Amiloride (5 mg)
Number of subjects: 44
Study: 30511430

Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste with amoxicillin (TAPa)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste with cefaclor (TAPc)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste with doxycycline (TAPd)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste with minocycline (TAPm)
Number of subjects: 50
Study: 28777242

Group type: EXPERIMENTAL
Intervention: NR1I2 rs3814055:C>T genotypes (CC, CT, TT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: TAC dose administered to minor T allele carriers (CT or TT genotype)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CYP3A5 expressers excluded from analysis
Number of subjects: 240
Study: 26033349

Group type: EXPERIMENTAL
Intervention: Mobile app and pedometer intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61